Tazarotene/ulobetasol

Drug Profile

Tazarotene/ulobetasol

Alternative Names: Halobetasol propionate/tazarotene; IDP-118; Tazarotene/halobetasol propionate; Ulobetasol/tazarotene

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dow Pharmaceutical Sciences
  • Developer Ortho Dermatologics
  • Class Antipsoriatics; Corticosteroids; Cyclopentanes; Keratolytics; Nicotinic-acids; Phenanthrenes; Pyridines; Retinoids; Small molecules
  • Mechanism of Action Retinoid X receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Plaque psoriasis

Most Recent Events

  • 05 Sep 2017 Preregistration for Plaque psoriasis in USA (Topical)
  • 05 Sep 2017 Efficacy and adverse events data from studies in Plaque psoriasis released by Ortho Dermatologics
  • 27 Jul 2017 Valeant Pharmaceuticals International acquired Ortho Dermatologics in 2011 and changed the name of the later to Valeant Dermatology. Subsequently, in July 2017, it was rebranded to Ortho Dermatologics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top